Trial Troubles for Alzheimer Drugs

Eli Lilly's solanezumab may be the first Alzheimer's disease modifying agent on the market if Expedition-3 is successful. Bloomberg Intelligence's Asthika Goonewardene reports on "Market Makers." (Source: Bloomberg)

Full Show: What'd You Miss? (08/11)
20:36 - Guests include: Peter Atwater, Financial Insyghts president, and Travis Briggs, ROBO Global chief executive officer. (Source: Bloomberg)
  • Bloomberg Markets: The Trump Economy 8/9/17
  • Full Show: Bloomberg Daybreak: Americas (08/08)
  • Bloomberg Markets: The Trump Economy 8/7/17